Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)

Br J Haematol. 2014 Jan;164(2):297-9. doi: 10.1111/bjh.12604. Epub 2013 Oct 17.

Authors

Brian T Hill¹, Paolo Caimi, Tammy Kindwall-Keller, Becky Habecker, Matt Kalaycio

Affiliation

¹ Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

PMID: 24131326
DOI: 10.1111/bjh.12604

No abstract available

Keywords: CLL; chemotherapy; monoclonal antibodies.

Publication types

Letter

MeSH terms

Alemtuzumab
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Nitrogen Mustard Compounds / administration & dosage
Treatment Outcome
Vidarabine / analogs & derivatives
Vidarabine / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Nitrogen Mustard Compounds
Alemtuzumab
Bendamustine Hydrochloride
Vidarabine
fludarabine